Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$42.57 USD

42.57
740,451

-0.06 (-0.14%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $42.57 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (172 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thermo Fisher (TMO) to Advance Precision Medicine in Qatar

by Zacks Equity Research

Thermo Fisher's (TMO) collaboration with Qatar Genome Program will utilize the power of genomics to enhance the standard of healthcare for the Qatari population.

Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger

by Zacks Equity Research

Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.

Here's Why Investors Should Retain Haemonetics (HAE) For Now

by Zacks Equity Research

Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.

Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals

by Zacks Equity Research

The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.

Catalent's (CTLT) Latest Facility Expansion to Boost Capacity

by Zacks Equity Research

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

by Zacks Equity Research

Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.

AMN Healthcare (AMN) Could Find Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

AMN Healthcare (AMN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Align Technology (ALGN) Debuts Invisalign Outcome Simulator Pro

by Zacks Equity Research

The next-generation of Align Technology's (ALGN) advanced patient communication tool will help patients see their potential new smile after Invisalign treatment.

Reasons to Retain DaVita (DVA) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

PerkinElmer (PKI) Boosts Genomic Testing Portfolio With urWGS

by Zacks Equity Research

PerkinElmer's (PKI) urWGS will improve outcomes for critically ill patients in NICUs and PICUs.

Catalent's (CTLT) New Launch to Enhance Gene Therapy Development

by Zacks Equity Research

Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.

Globus Medical (GMED) Completes First Cases With Excelsius3D

by Zacks Equity Research

Globus Medical's (GMED) Excelsius3D, when combined with ExcelsiusGPS, facilitates greater implant placement accuracy, lowers radiation exposure and reduces operative times.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

Here's Why Investors Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) better-than-expected results and robust segmental growth.

QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio

by Zacks Equity Research

The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.

NextGen Healthcare (NXGN) Q4 Earnings Miss Mark, Revenues Beat

by Zacks Equity Research

NextGen Healthcare's (NXGN) fiscal fourth-quarter earnings reflect strength in its Recurring revenues.

BD (BDX) Introduces New Molecular Diagnostic Platform in US

by Zacks Equity Research

BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments.

Reasons to Add Patterson Companies (PDCO) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet's (ZBH) better-than-expected revenues and robust performance across several geographies.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Philips' (PHG) Launches a Range of New Products at EuroPCR 2022

by Zacks Equity Research

Philips' (PHG) launches innovative new solutions to attract customers amid a global supply crunch and drive top-line growth.

Community Health (CYH) Boosts Obstetrics Care With Technology

by Zacks Equity Research

Community Health (CYH) employs PeriGen's technology to bring about enhanced obstetrics services and assure the safety of mothers as well as babies in the labor and delivery procedures.

AMN Healthcare's (AMN) New Buyout to Aid Healthcare Staffing

by Zacks Equity Research

AMN Healthcare's (AMN) acquisition of Connetics USA is expected to significantly boost its Nurse and Allied Solutions segment globally.